129 results on '"Pala, Laura"'
Search Results
2. Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis
3. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
4. Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
5. Correction to: Orthorexia nervosa and type 1 diabetes: results of a cross‑sectional study
6. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]
7. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
8. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
9. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
10. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
11. Table S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
12. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
13. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
14. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
15. Figure S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
16. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
17. Table S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
18. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
19. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
20. Figure S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
21. Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
22. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
23. High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study
24. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
25. Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
26. Patient-Reported Outcomes of COVID-19 Vaccine Breakthrough Infection–Associated Changes in Glucose Control in Subjects With Type 1 Diabetes (PRO-VACS 2 Study)
27. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
28. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
29. Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action
30. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy
31. Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials
32. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials
33. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
34. Endocrine System and Cardiovascular Disease
35. Sex and cancer immunotherapy: Current understanding and challenges
36. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
37. Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
38. Boosting anticancer immunotherapy through androgen receptor blockade
39. Therapeutic Education
40. Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study
41. Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS)
42. Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study
43. Assessment of left ventricular Global Longitudinal Strain in patients with type 2 diabetes: relationship with microvascular damage and glycemic control
44. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
45. Different Response to Immunotherapy According to Melanoma Histologic Subtype
46. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations
47. Coordination Chemistry and Sensing Properties Towards Anions and Metal Ions of a Simple Fluorescent Urea
48. The effect of patient sex on the efficacy and safety of anticancer immunotherapy
49. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort
50. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.